|
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
4 July 2006 | Volume 145 Issue 1 | Pages 62-69
Active-control noninferiority trials are being performed with increasing frequency when standard placebo-controlled trials are considered unethical. Three attributes are optimally required to establish noninferiority: 1) The treatment under consideration exhibits therapeutic noninferiority to the active control; 2) the treatment would exhibit therapeutic efficacy in a placebo-controlled trial if such a trial were to be performed; and 3) the treatment offers ancillary advantages in safety, tolerability, cost, or convenience. Trials designed to show noninferiority require an appropriate reference population, a proven active control and dose, a high level of adherence to treatment, and adequate statistical power. However, the formal analysis of such trials is founded on several assumptions that cannot be validated explicitly. These assumptions are evaluated in the context of 8 recently published noninferiority trials. The analyses in this paper confirm the establishment of noninferiority in only 4 of the 8 trials. The authors conclude that if noninferiority trials are to be applied to clinical and regulatory decisions about the marketing and use of new treatments, these assumptions must be made explicit and their influence on the resultant conclusions assessed rigorously.
Author and Article Information
From Cedars-Sinai Medical Center and David Geffen School of Medicine, University of California, Los Angeles, California.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Sanjay Kaul, MD, Division of Cardiology, Room 5536, South Tower, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048; e-mail, kaul{at}cshs.org.
Current Author Addresses: Drs. Kaul and Diamond: Division of Cardiology, Room 5536, South Tower, Cedars-Sinai Medical Center, 8700 Beverly Boulevard, Los Angeles, CA 90048. ACADEMIA AND CLINIC
Good Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
![]()
This article has been cited by other articles:
![]() |
P. E. Greilich, M. E. Jessen, N. Satyanarayana, C. W. Whitten, G. A. Nuttall, J. M. Beckham, M. H. Wall, and J. F. Butterworth The Effect of Epsilon-Aminocaproic Acid and Aprotinin on Fibrinolysis and Blood Loss in Patients Undergoing Primary, Isolated Coronary Artery Bypass Surgery: A Randomized, Double-Blind, Placebo-Controlled, Noninferiority Trial Anesth. Analg., July 1, 2009; 109(1): 15 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Farjah, D. E. Wood, M. S. Mulligan, B. Krishnadasan, P. J. Heagerty, R. G. Symons, and D. R. Flum Safety and efficacy of video-assisted versus conventional lung resection for lung cancer. J. Thorac. Cardiovasc. Surg., June 1, 2009; 137(6): 1415 - 1421. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. DeMaria Lies, Damned Lies, and Statistics J. Am. Coll. Cardiol., October 21, 2008; 52(17): 1430 - 1431. [Full Text] [PDF] |
||||
![]() |
P. M. Ho, P. N. Peterson, and F. A. Masoudi Evaluating the Evidence: Is There a Rigid Hierarchy? Circulation, October 14, 2008; 118(16): 1675 - 1684. [Full Text] [PDF] |
||||
![]() |
D. E. Singer, G. W. Albers, J. E. Dalen, M. C. Fang, A. S. Go, J. L. Halperin, G. Y. H. Lip, and W. J. Manning Antithrombotic Therapy in Atrial Fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest, June 1, 2008; 133(6_suppl): 546S - 592S. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. J.V. McMurray ACE Inhibitors in Cardiovascular Disease -- Unbeatable? N. Engl. J. Med., April 10, 2008; 358(15): 1615 - 1616. [Full Text] [PDF] |
||||
![]() |
J. C. Victor, A. S. Monto, T. Y. Surdina, S. Z. Suleimenova, G. Vaughan, O. V. Nainan, M. O. Favorov, H. S. Margolis, and B. P. Bell Hepatitis A Vaccine versus Immune Globulin for Postexposure Prophylaxis N. Engl. J. Med., October 25, 2007; 357(17): 1685 - 1694. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Reddy, S. S. Gill, S. R. Kalkar, W. Wu, P. J. Anderson, and P. A. Rochon Oral Drug Therapy for Multiple Neglected Tropical Diseases: A Systematic Review JAMA, October 24, 2007; 298(16): 1911 - 1924. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. A. Diamond and S. Kaul COURAGE Under Fire: On the Management of Stable Coronary Disease J. Am. Coll. Cardiol., October 16, 2007; 50(16): 1604 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Farjah and D. R. Flum When Not Being Superior May Not Be Good Enough JAMA, August 22, 2007; 298(8): 924 - 925. [Full Text] [PDF] |
||||
![]() |
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): e1 - e157. [Full Text] [PDF] |
||||
![]() |
J. L. Anderson, C. D. Adams, E. M. Antman, C. R. Bridges, R. M. Califf, D. E. Casey Jr, W. E. Chavey II, F. M. Fesmire, J. S. Hochman, T. N. Levin, et al. ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine J. Am. Coll. Cardiol., August 14, 2007; 50(7): 652 - 726. [Full Text] [PDF] |
||||
![]() |
D. B. Ross The FDA and the Case of Ketek N. Engl. J. Med., April 19, 2007; 356(16): 1601 - 1604. [Full Text] [PDF] |
||||
![]() |
A. C. Wolff and N. E. Davidson Still Waiting After 110 Years: The Optimal Use of Ovarian Ablation As Adjuvant Therapy for Breast Cancer J. Clin. Oncol., November 1, 2006; 24(31): 4949 - 4951. [Full Text] [PDF] |
||||
![]() |
L. J. Appel A Primer on the Design, Conduct, and Interpretation of Clinical Trials Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1360 - 1367. [Abstract] [Full Text] [PDF] |
||||